Our studies of combination therapies targeting RASG12C(ON), SHP2 and immune checkpoints in preclinical models support clinical evaluation to assess their potential for improving clinical outcomes in lung cancer, providing the challenges of avoiding adverse toxicities can be addressed. This evidence concerns the gene PTPN11 and lung carcinoma.